newsfilter
← Interviews
Milken Institute1h 1m

Biotech: Bull Market or Bubble?

Luke Timmerman, Alex Denner, Bob Hugin, Annalisa Jenkins, John Reed

Conference Presentation, Panel

Panelists from major pharmaceutical firms and investment firms analyzed the biotech sector's transition from a 2012–2015 valuation bubble to a value-driven correction that prioritizes clinical utility over speculative hype. Industry leaders emphasized that while technological convergence in genomics and personalized medicine drives innovation, the sector faces critical challenges in pricing models, R&D efficiency, and patient trial enrollment that threaten long-term profitability. Consensus among the executives suggests that future success depends on collaborative regulatory frameworks, demonstrable patient outcomes, and new manufacturing efficiencies to justify the billions required for drug development.